CS
MRNS

Credit Suisse’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Credit Suisse’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20
Closed – – 4391
2022
Q2 		$0 Buy
+20
New +$122 ﹤0.01% 4438
2022
Q1 		– Sell
-655
Closed -$7K – 4460
2021
Q4 		$7K Buy
+655
New +$7.56K ﹤0.01% 4465
2019
Q4 		– Sell
-2,983
Closed -$18K – 4373
2019
Q3 		$18K Buy
2,983
+23
+0.8% +$186 ﹤0.01% 4089
2019
Q2 		$49K Buy
+2,960
New +$51.4K ﹤0.01% 4001
2018
Q4 		– Sell
-258,332
Closed -$10.3M – 4045
2018
Q3 		$10.3M Buy
258,332
+224,945
+674% +$6.4M 0.01% 1230
2018
Q2 		$944K Buy
+33,387
New +$740K ﹤0.01% 3048
2016
Q1 		– Sell
-9,174
Closed -$280K – 4343
2015
Q4 		$280K Sell
9,174
-15,580
-63% -$457K ﹤0.01% 3717
2015
Q3 		$826K Buy
24,754
+19,317
+355% +$1.09M ﹤0.01% 2989
2015
Q2 		$252K Buy
+5,437
New +$203K ﹤0.01% 4104

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Credit Suisse's MRNS Position: Q3 2022 in Review

Credit Suisse sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2022, closing a stake of 20 shares.

Credit Suisse first reported a position in MRNS in Q2 2015 and held it in 9 quarters. The position peaked at $10.3M in Q3 2018. 69 funds tracked by Wall St. Rank hold MRNS as of Q3 2022.

  • Credit Suisse reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 20 Marinus Pharmaceuticals, Inc shares in Q3 2022.
  • Credit Suisse first reported a position in Marinus Pharmaceuticals, Inc in Q2 2015 and held it in 9 quarters.
  • Credit Suisse's Marinus Pharmaceuticals, Inc position peaked at $10.3M in Q3 2018.
  • 69 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.